$VKTX Full reversal from HIMs
“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims said”
From Apple News
$VKTX For me it’s interesting that this year the wording from Viking has changed from “Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial” to now saying
“Concurrently, the company is evaluating an oral formulation of VK2735 in obesity”
@lipa0902@MeadowCapital Yeah, just ignore the positive meeting and no Ph2b for 2735 Subq. This is a really poor example of trying to find negative context. Very poor, must to better.
$VKTX literally hundreds of posts from this guy, since he first appeared spouting “single figures” and “FDA issues”.
Viking moved +46% since he started posting negatively.
That must hurt and is just stupid; money lost with every post.
@GMEshortsqueeze@Stocktwits@wallstreetbets $VKTX - April update they still use 12/31 cash balance, required by law to update 3/31. $95 to $19.85, CEO/CFO/COO delayed/drip data so they could dump their shares, 85 Inst buyers were deceived. Heading to single digit
@Mufaso7@mark1eddie He did say in an update q&a about amylin and 2735 being special. Said the first trial would be amylin alone then a quad. I think
@Mufaso7 Great post. I think what also completely surprised some of the analysts was that there is no second titration on the switch from subq to oral. This makes ViK2735 in my opinion. Imagine a subq weight loss and then just one pill a week to keep the weight loss off!
Shorts inadvertently positioned themselves as coiled spring and amplify any news. Shorts thought to be retail, hedges betting on VKTX “too late” and technical traders on chart breakdowns.
Positive Ph2 (8-12%) plus BO rumour creates up to $12bn loss for shorts from resulting BO
$VKTX
Talk me out of this scenario:
VKtX release Ph2 on 26 Aug prior to 4 major pre planned Sept presentations which give BP opportunity to deal
All short reasons, obesity overcrowding, VKTX lateness, production, LLY/NVO superiority now flipped
TAM of $100bn+ sees $50bn BO
$VKTX
Cash deal (PFE, Merck, J&J) doesn’t need shareholder approval. Triggers immediate share price to BO price as 28m shares cover (26% of float) No rolling of short positions to acquirers stock. Immediate margin calls see short cover in open market and stock returned to lender